Spots Global Cancer Trial Database for Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLC

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLC

Official Title: Erlotinib Treatment Beyond Progression in EGFR Mutant or Patients Who Have Responded EGFR TKI in Stage IIIB/IV NSCLC

Study ID: NCT02064491

Conditions

Non-small Cell Lung Cancer

Interventions

Erlotinib

Chemotherapy

Study Description

Brief Summary: The purpose of this study is to determine whether continuing erlotinib beyond disease progression in combination with chemotherapy is beneficial for NSCLC patients who have EGFR mutant disease or who have responded to EGFR TKI.

Detailed Description: A Phase II randomised, multicenter study to assess the efficacy and safety of continuing erlotinib in addition to chemotherapy versus chemotherapy alone in patients who have EGFR mutant or EGFR TKI responsive NSCLC and have progressed on EGFR TKI.